VIM0423 for adults with isolated dystonia affecting multiple body regions
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)
Run by Vima Therapeutics · NCT07304089 · Data updated 2026-11-12
This trial will test a once-daily oral medicine called VIM0423 to see if it reduces dystonia symptoms and improves daily function in adults with isolated dystonia that affects two or more body regions.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Vima Therapeutics Industry-sponsored |
| Locations | 45 sites (Birmingham, Alabama and 44 other locations) |
| Status | Recruiting |
| Started | February 5, 2026 |
| Main results expected | March 2027 |
| Study ends | May 2027 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT07304089 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–65 with a clinical diagnosis of isolated dystonia for at least one year and two or more affected body regions who meet baseline rating-scale criteria (and stable or no botulinum toxin treatment per protocol) are ideal candidates.
✕Probably not a fit
People whose dystonia affects only a single region, those outside the 18–65 age range, pregnant individuals, or those with secondary dystonia are unlikely to be eligible or to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Stride Dystonia (VIM0423-201) is a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial testing once-daily oral VIM0423 in adults with isolated dystonia affecting two or more body regions. VIM0423 is intended to correct a chemical imbalance in brain regions thought to cause dystonia. About 120 participants will be randomized to VIM0423 or placebo and followed for measures of symptom severity, daily function, and quality of life while safety and tolerability are monitored. Key outcome measures include dystonia rating scales (e.g., BFM), clinician global impression, patient-reported function, and adverse events.
Why it matters
Potential benefit: If effective, VIM0423 could provide the first oral therapy that reduces dystonia symptoms across multiple body regions and improves daily function and quality of life.
How similar studies have gone: Approved botulinum toxin injections work for some focal dystonias, and prior oral medications have given limited or inconsistent benefit, so an oral drug that treats multiple regions would be a relatively novel but plausible advance.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant must be male or nonpregnant female between 18 and 70 years of age (inclusive) at Visit 1 (Screening). * The participant has a clinical diagnosis of isolated dystonia with symptoms consistent with dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee. * The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria. * The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.
Where it's running
-
Vima Site #033
Birmingham, Alabama, United States Recruiting -
Vima Site #039
Scottsdale, Arizona, United States Recruiting -
Vima Site #004
Scottsdale, Arizona, United States Recruiting -
Vima Site #028
Sun City, Arizona, United States Recruiting -
Vima Site #042
Irvine, California, United States Recruiting -
Vima Site #030
Los Angeles, California, United States Recruiting
Show 39 more locations
-
Vima Site #019
Denver, Colorado, United States Recruiting -
Vima Site #009
Gainesville, Florida, United States Recruiting -
Vima Site #008
Miami, Florida, United States Recruiting -
Vima Site #031
Orlando, Florida, United States Recruiting -
Vima Site #005
Atlanta, Georgia, United States Recruiting -
Vima Site #027
Chicago, Illinois, United States Recruiting -
Vima Site #041
Overland Park, Kansas, United States Recruiting -
Vima Site #043
Baltimore, Maryland, United States Recruiting -
Vima Site #007
Olney, Maryland, United States Recruiting -
Vima Site #032
Boston, Massachusetts, United States Recruiting -
Vima Site #037
East Lansing, Michigan, United States Recruiting -
Vima Site #002
Farmington Hills, Michigan, United States Recruiting -
Vima Site #038
St Louis, Missouri, United States Recruiting -
Vima Site #014
Albuquerque, New Mexico, United States Recruiting -
Vima Site #018
New York, New York, United States Recruiting -
Vima Site #024
New York, New York, United States Recruiting -
Vima Site #036
Rochester, New York, United States Recruiting -
Vima Site #040
Fayetteville, North Carolina, United States Recruiting -
Vima Site #035
Cincinnati, Ohio, United States Recruiting -
Vima Site #029
Portland, Oregon, United States Recruiting -
Vima Site #020
Philadelphia, Pennsylvania, United States Recruiting -
Vima Site #021
Charleston, South Carolina, United States Recruiting -
Vima Site #016
Memphis, Tennessee, United States Recruiting -
Vima Site #006
Nashville, Tennessee, United States Recruiting -
Vima Site #025
Dallas, Texas, United States Recruiting -
Vima Site #026
Georgetown, Texas, United States Recruiting -
Vima Site #012
Houston, Texas, United States Recruiting -
Vima Site #013
Houston, Texas, United States Recruiting -
Vima Site #011
Richmond, Virginia, United States Recruiting -
Vima Site #023
Kirkland, Washington, United States Recruiting -
Vima Site #015
Spokane, Washington, United States Recruiting -
Vima Site #061
Sacramento, California, United States Not yet recruiting -
Vima Site #056
Aurora, Colorado, United States Not yet recruiting -
Vima Site #069
Vernon, Connecticut, United States Not yet recruiting -
Vima Site #055
Amherst, New York, United States Not yet recruiting -
Vima Site #059
Calgary, Alberta, Canada Not yet recruiting -
Vima Site #068
Vancouver, British Columbia, Canada Not yet recruiting -
Vima Site #070
Ottawa, Ontario, Canada Not yet recruiting -
Vima Site #060
Toronto, Ontario, Canada Not yet recruiting
Study contacts
- Study coordinator: Study Director
- Email: Clinicaltrials@vimatx.com
- Phone: 617-430-7027
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating the relationship between genetic mutations and brain changes in dystonia
This study is trying to see how genetic changes linked to dystonia affect the brain in people with the condition compared to healthy individuals.
-
Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment
This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.
-
Low-intensity focused ultrasound for movement and seizure disorders
This trial will try low-intensity focused ultrasound (LIFUS) to see if it can safely change brain activity in people with movement disorders or epilepsy.
-
Measuring brain network activity to predict and improve outcomes in children with dystonia
This project will test whether noninvasive brain and muscle recordings, and comparing DBS on versus off, can predict and help improve motor outcomes for children with dystonia.
-
Wearable sensors to predict DBS results for people with dystonia
This study will test whether wearable sensors that record walking patterns before surgery can predict how well deep brain stimulation will work for people with dystonia.
-
Using GPi brain signals to guide DBS programming for primary dystonia
This study will test whether recording local field potentials from the globus pallidus interna with the Medtronic Percept device can help guide DBS programming and improve symptoms in adults with primary dystonia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.